(HealthDay)—Life expectancy in the United States has declined for two years in a row, fueled by increasing death rates from
Continue reading »
Home » Medications »
Potentially inappropriate opioid prescribing tied to overdose
(HealthDay)—Potentially inappropriate prescribing (PIP) of opioids is associated with increased risk of all-cause mortality and fatal and nonfatal overdose, according
Continue reading »
Fear of police stop and search can deter opioid users from carrying anti-overdose kits
The levels of fatal overdose in the UK are catastrophic. More than 4,500 people died of a drug-related death in
Continue reading »
Screen strategies for off-target liability prediction and identifying small-molecule pharmaceuticals
A new review in SLAS Discovery explores how improved safety screening strategies and methods are improving the pharmaceutical discovery and
Continue reading »
A new generation of pain medication
Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medication. The researchers used computer simulations
Continue reading »
Argenx Doses First Patient in Global Phase 3 Registration Trial of Efgartigimod
September 06, 2018 — Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company
Continue reading »
Antidepressants may cause antibiotic resistance
A key ingredient in common antidepressants such as Prozac could be causing antibiotic resistance according to new University of Queensland
Continue reading »
FDA Approves Pifeltro
KENILWORTH, N.J.–(BUSINESS WIRE) August 30, 2018 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced
Continue reading »
Scientists take big step toward finding non-addictive painkiller
With the support of the National Institute on Drug Abuse, scientists at Wake Forest School of Medicine have been working
Continue reading »
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved Gut Microbiome of Patients with CDI
Oxford, UK, and Cambridge, MA, US, 3 August 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the publication
Continue reading »